Talphera (TLPH) Competitors $0.83 +0.03 (+4.33%) Closing price 04:00 PM EasternExtended Trading$0.85 +0.01 (+1.71%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLPH vs. ADAG, ENLV, PYXS, PRQR, and LFCRShould you buy Talphera stock or one of its competitors? MarketBeat compares Talphera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Talphera include Adagene (ADAG), Enlivex Therapeutics (ENLV), Pyxis Oncology (PYXS), ProQR Therapeutics (PRQR), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. TLPH vs. ADAGTLPH vs. ENLVTLPH vs. PYXSTLPH vs. PRQRTLPH vs. LFCRHow does Talphera compare to Adagene?Talphera (NASDAQ:TLPH) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation. Does the media refer more to TLPH or ADAG? In the previous week, Talphera had 9 more articles in the media than Adagene. MarketBeat recorded 10 mentions for Talphera and 1 mentions for Adagene. Talphera's average media sentiment score of 0.48 beat Adagene's score of 0.00 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adagene 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in TLPH or ADAG? 37.7% of Talphera shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, TLPH or ADAG? Talphera has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Adagene has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Do analysts prefer TLPH or ADAG? Talphera currently has a consensus price target of $3.00, indicating a potential upside of 260.66%. Adagene has a consensus price target of $8.00, indicating a potential upside of 135.29%. Given Talphera's higher possible upside, analysts plainly believe Talphera is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Adagene 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has better earnings & valuation, TLPH or ADAG? Talphera has higher earnings, but lower revenue than Adagene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$1K43,170.42-$14.29M-$0.31N/AAdagene$7.67M21.01-$17.61MN/AN/A Is TLPH or ADAG more profitable? Adagene's return on equity of 0.00% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -92.98% -53.22% Adagene N/A N/A N/A SummaryTalphera and Adagene tied by winning 7 of the 14 factors compared between the two stocks.How does Talphera compare to Enlivex Therapeutics?Enlivex Therapeutics (NASDAQ:ENLV) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Is ENLV or TLPH more profitable? Enlivex Therapeutics' return on equity of 248.08% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A 248.08% 206.39% Talphera N/A -92.98%-53.22% Does the media refer more to ENLV or TLPH? In the previous week, Talphera had 7 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 10 mentions for Talphera and 3 mentions for Enlivex Therapeutics. Talphera's average media sentiment score of 0.48 beat Enlivex Therapeutics' score of 0.25 indicating that Talphera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Talphera 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, ENLV or TLPH? Enlivex Therapeutics has higher earnings, but lower revenue than Talphera. Talphera is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A$1.24B-$0.55N/ATalphera$1K43,170.42-$14.29M-$0.31N/A Which has more risk & volatility, ENLV or TLPH? Enlivex Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Talphera has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Do institutionals & insiders believe in ENLV or TLPH? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts prefer ENLV or TLPH? Enlivex Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 2,242.09%. Talphera has a consensus target price of $3.00, indicating a potential upside of 260.66%. Given Enlivex Therapeutics' higher probable upside, equities research analysts plainly believe Enlivex Therapeutics is more favorable than Talphera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Talphera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryEnlivex Therapeutics beats Talphera on 7 of the 12 factors compared between the two stocks.How does Talphera compare to Pyxis Oncology?Talphera (NASDAQ:TLPH) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations. Which has preferable valuation & earnings, TLPH or PYXS? Talphera has higher earnings, but lower revenue than Pyxis Oncology. Talphera is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$1K43,170.42-$14.29M-$0.31N/APyxis Oncology$13.86M8.66-$79.62M-$1.31N/A Which has more volatility & risk, TLPH or PYXS? Talphera has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Do analysts prefer TLPH or PYXS? Talphera currently has a consensus price target of $3.00, indicating a potential upside of 260.66%. Pyxis Oncology has a consensus price target of $6.83, indicating a potential upside of 257.77%. Given Talphera's higher possible upside, research analysts clearly believe Talphera is more favorable than Pyxis Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Do institutionals and insiders believe in TLPH or PYXS? 37.7% of Talphera shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TLPH or PYXS more profitable? Talphera's return on equity of -92.98% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -92.98% -53.22% Pyxis Oncology N/A -135.60%-85.00% Does the media refer more to TLPH or PYXS? In the previous week, Pyxis Oncology had 11 more articles in the media than Talphera. MarketBeat recorded 21 mentions for Pyxis Oncology and 10 mentions for Talphera. Talphera's average media sentiment score of 0.48 beat Pyxis Oncology's score of 0.12 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pyxis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryPyxis Oncology beats Talphera on 8 of the 15 factors compared between the two stocks.How does Talphera compare to ProQR Therapeutics?Talphera (NASDAQ:TLPH) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership. Is TLPH or PRQR more profitable? Talphera has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. ProQR Therapeutics' return on equity of -84.87% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -92.98% -53.22% ProQR Therapeutics -331.33%-84.87%-37.78% Does the media prefer TLPH or PRQR? In the previous week, Talphera had 6 more articles in the media than ProQR Therapeutics. MarketBeat recorded 10 mentions for Talphera and 4 mentions for ProQR Therapeutics. Talphera's average media sentiment score of 0.48 beat ProQR Therapeutics' score of 0.30 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, TLPH or PRQR? Talphera has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Which has better valuation & earnings, TLPH or PRQR? Talphera has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$1K43,170.42-$14.29M-$0.31N/AProQR Therapeutics$17.99M8.37-$47.73M-$0.50N/A Do insiders and institutionals have more ownership in TLPH or PRQR? 37.7% of Talphera shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend TLPH or PRQR? Talphera currently has a consensus target price of $3.00, indicating a potential upside of 260.66%. ProQR Therapeutics has a consensus target price of $7.25, indicating a potential upside of 406.99%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Talphera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 SummaryTalphera beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks.How does Talphera compare to Lifecore Biomedical?Lifecore Biomedical (NASDAQ:LFCR) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Do analysts prefer LFCR or TLPH? Lifecore Biomedical presently has a consensus price target of $6.00, suggesting a potential upside of 36.99%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 260.66%. Given Talphera's higher probable upside, analysts plainly believe Talphera is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifecore Biomedical 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20Talphera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, LFCR or TLPH? Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Talphera has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Which has preferable valuation and earnings, LFCR or TLPH? Talphera has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifecore Biomedical$128.87M1.27-$35.26M-$0.94N/ATalphera$1K43,170.42-$14.29M-$0.31N/A Is LFCR or TLPH more profitable? Talphera has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Talphera's return on equity of -92.98% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Lifecore Biomedical-25.43% -1,643.15% -14.40% Talphera N/A -92.98%-53.22% Does the media favor LFCR or TLPH? In the previous week, Talphera had 10 more articles in the media than Lifecore Biomedical. MarketBeat recorded 10 mentions for Talphera and 0 mentions for Lifecore Biomedical. Talphera's average media sentiment score of 0.48 beat Lifecore Biomedical's score of 0.00 indicating that Talphera is being referred to more favorably in the news media. Company Overall Sentiment Lifecore Biomedical Neutral Talphera Neutral Do insiders & institutionals believe in LFCR or TLPH? 83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryTalphera beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition ExportMetricTalpheraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.17M$2.97B$6.25B$12.10BDividend YieldN/A1.98%2.80%5.32%P/E Ratio-2.6817.0420.5825.09Price / Sales43,170.42571.54577.4291.07Price / CashN/A56.3527.4837.30Price / Book2.253.919.686.60Net Income-$14.29M$74.99M$3.55B$335.71M7 Day Performance-3.00%-4.89%-2.07%-2.03%1 Month Performance3.64%-8.30%-3.90%-1.90%1 Year Performance63.13%28.66%29.39%27.36% Talphera Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera3.4866 of 5 stars$0.83+4.3%$3.00+260.7%+58.2%$43.17M$1KN/A19Earnings ReportADAGAdagene2.2081 of 5 stars$3.66-3.4%$8.00+118.6%+91.5%$179.59M$7.67MN/A260News CoveragePositive NewsGap DownENLVEnlivex Therapeutics2.38 of 5 stars$0.75+0.8%$16.50+2,102.1%-30.3%$176.42MN/AN/A70News CoveragePYXSPyxis Oncology3.3106 of 5 stars$2.60-5.5%$6.83+162.8%+66.9%$172.85M$13.86MN/A60Trending NewsEarnings ReportUpcoming EarningsAnalyst DowngradeAnalyst RevisionPRQRProQR Therapeutics3.4036 of 5 stars$1.60-0.6%$7.25+353.1%-6.8%$169.63M$17.99MN/A180Earnings ReportAnalyst Downgrade Related Companies and Tools Related Companies Adagene Alternatives Enlivex Therapeutics Alternatives Pyxis Oncology Alternatives ProQR Therapeutics Alternatives Lifecore Biomedical Alternatives Black Diamond Therapeutics Alternatives Molecular Partners Alternatives Korro Bio Alternatives Immunic Alternatives Oncocyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLPH) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
